IMPACT OF SUPPLEMENTATION WITH LOW MOLECULAR WEIGHT HYDROLYZED COLLAGEN AND VERISOL ON THE EXPRESSION OF LINES, SKIN QUALITY, AND LEVELS OF KLOTHO, VEGF, AND TGF-BETA IN THE EYE REGION

NCT06971029 | Not Yet Recruiting Phase 4

• 1 other identifier: 7.233.377
• Study Type: interventional
• Target: 150
• Locations: 0 countries
• Sites: N/A

Brief Summary

Skin is the largest organ of the human body and performs various vital functions, including protection against external agents, regulation of body temperature, and sensory perception. As we age, our skin undergoes a series of changes that can be noticeable both visually and physically. One of the most evident changes is the appearance of wrinkles and fine lines, resulting from decreased skin elasticity and reduced production of collagen and elastin. Nutrition plays a key role in skin health, influencing its structure, function, and ability to defend against damage and diseases. However, it is unknown to what extent supplementation with different types of collagens can attenuate these effects in middle-aged women. Therefore, the present study aims to recruit 150 middle-aged women (35-58 years old) who will be randomized into three groups, Verisol Collagen 2.5 g/day, Peptech Collagen 2.5 g/day, and Peptech Collagen 10 g/day, 7 days a week, for 3 months. Skin hydration, oiliness, and flexibility, as well as the number and depth of expression lines, will be evaluated, along with plasma levels of Klotho, VEGF, and TGF-beta. Data will be analyzed, and graphs constructed using GraphPad Prism 5.0 software (California, USA). The normality distribution of the data will be assessed by the Kolmogorov-Smirnov test. Data with parametric distribution will be subjected to paired Student's t-test for intragroup comparison, and unpaired t-test will be used for comparison between groups. Significance levels will be considered statistically different for p\<0.05.

Conditions

Skin Health; Collagen Supplementation; Growth Factors

Keywords

Skin health; collagen supplementation; growth factors

Outcome Measures

Primary Outcomes (1)

• Plasma levels of Klotho, VEGF, and TGF-beta

  Three months.

Study Arms (4)

Verisol Collagen 2.5 g/day

EXPERIMENTAL

Supplementation with Verisol® collagen will be administered at a dose of 2.5 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.

Dietary Supplement: Supplementation with Verisol®

Peptech Collagen 2.5 g/day (GCP 2.5)

EXPERIMENTAL

Supplementation with Peptech® collagen will be administered at a dose of 2.5 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.

Dietary Supplement: Supplementation with Peptech® 2.5G

eptech Collagen 10 g/day (GCP 10)

EXPERIMENTAL

Supplementation with Peptech® collagen will be administered at a dose of 10.0 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.

Dietary Supplement: Supplementation with Peptech® 10.0G

Group Control

OTHER

he control group will undergo the tests but will not receive supplementation.

Diagnostic Test: Control group

Interventions

Supplementation with Verisol® DIETARY_SUPPLEMENT

Supplementation with Verisol® collagen will be administered at a dose of 2.5 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.

Verisol Collagen 2.5 g/day

Supplementation with Peptech® 2.5G DIETARY_SUPPLEMENT

Supplementation with Peptech® collagen will be administered at a dose of 2.5 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.

Peptech Collagen 2.5 g/day (GCP 2.5)

Supplementation with Peptech® 10.0G DIETARY_SUPPLEMENT

Supplementation with Peptech® collagen will be administered at a dose of 10.0 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.

eptech Collagen 10 g/day (GCP 10)

Control group DIAGNOSTIC_TEST

The control group will not receive supplementation.

Group Control

Eligibility Criteria

• Age: 35 Years - 58 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

Sponsors & Collaborators

• Federal University of São Paulo: lead

Related Publications (2)

• Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol. 2008 Dec;17(12):1063-72. doi: 10.1111/j.1600-0625.2008.00786.x.

  PMID: 19043850 RESULT

• Paula-Vieira RHR, Dias SR, Silva-Reis A, Moura-Maia MS, Ramos-Gomes NV, Jesus-Silva K, Oliveira-Leal YR, Castro-Pimentel LT, Carvalho WSF, Melo F, Martins JLR, Bachi ALL, Vieira RP. Immune-Modulatory Effects of Bioactive Collagen Peptides Improve Skin Health in Middle-Aged Women. Dermatol Ther (Heidelb). 2026 Jan 27. doi: 10.1007/s13555-026-01654-9. Online ahead of print.

  PMID: 41588262 DERIVED

MeSH Terms

Interventions

Dietary Supplements

Intervention Hierarchy (Ancestors)

Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages

Central Study Contacts

Luis Vicente Franco de Oliveira Coordinator of the Stricto Sensu Graduate Program in Human Mov

CONTACT

(62)3310-6736; luis.oliveira@unievangelica.edu.br

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. Dr.

Model Details: The 150 volunteers will be randomized into three groups (n = 50/group): Verisol Collagen 2.5 g/day (GCV), Peptech Collagen 2.5 g/day (GCP 2.5), and Peptech Collagen 10 g/day (GCP 10).

Study Record Dates

• First Submitted: May 6, 2025
• First Posted: May 14, 2025
• Study Start: June 9, 2025
• Primary Completion: September 1, 2025
• Study Completion: December 1, 2025
• Last Updated: May 14, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share